Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sohini Mondal

HISTORICAL FACTS: Earnings preview what to expect from biogen s report - The Untold Story

With a market cap of $17.4 billion, Biogen Inc. (BIIB) is a global biotechnology leader focused on discovering, developing, and delivering innovative therapies for serious neurological and neurodegenerative diseases. Its portfolio includes treatments for multiple sclerosis, spinal muscular atrophy (Spinraza), Alzheimer’s disease (Aduhelm), ALS (QALSODY), and several biosimilars, with active collaborations across the biotech industry. BIIB is set to unveil its fiscal Q1 2025 earnings results before the market opens on Thursday, May 1.

Ahead of this event, analysts expect the Cambridge, Massachusetts-based company to report a profit of $3.34 per share, down nearly 9% from $3.67 per share in the year-ago quarter. However, the company has surpassed Wall Street's bottom-line estimates in the past four quarters. In Q4 2024, BIIB exceeded the consensus EPS estimate by a slight margin.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.